[The treatment of chronic myeloleukemia with recombinant alfa-2 interferon].
A trial has been conducted of recombinant alpha 2-interferon (reaferon) used in 32 patients with Ph'[correction of Rh']-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed. The treatment lasted from 2 months to 3 years. Clinicohematological remission was confirmed conventionally and by the degree of Ph'-positive clone reduction. An attempt is made to clarify the mechanism underlying the resistance to reaferon basing on the immunological data (detection of antireaferon neutralizing antibodies). The authors propose a combined treatment (myelosan plus reaferon) of CML which has obvious advantages over myelosan monotherapy.
Strozha
I
I
Petukhov
V
V
Bondare
D
D
Feldmane
G
G
Duks
A
A
Teilane
I
I
Medne
I
I
Mauritsas
M
M
Grinberga
L
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D001752:Blast Crisis / Q000097:blood / Q000628:therapy*; D002648:Child; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Lechenie khronicheskogo mieloleĭkoza rekombinantnym al'fa 2-interferonom.